Drug induced QT prolongation and torsades de pointes - Test2 - elhamkhani - TriplyDB

Drug induced QT prolongation and torsades de pointes

Drug induced QT prolongation and torsades de pointes

http://www.wikidata.org/entity/Q24673854

about

Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development Calculate the QT interval in patients taking drugs for dementia Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment Optimal antiarrhythmic drug therapy for electrical storm A study of early afterdepolarizations in a model for human ventricular tissue.Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator.Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials Treating arrhythmias with adjunctive magnesium: identifying future research directions Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management Acute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation study Pharmacometabolomic approach to predict QT prolongation in guinea pigs Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial A Framework of Knowledge Integration and Discovery for Supporting Pharmacogenomics Target Predication of Adverse Drug Events: A Case Study of Drug-Induced Long QT Syndrome Drug- and non-drug-associated QT interval prolongation.Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.Generalized estimating equations for genome-wide association studies using longitudinal phenotype data.Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.Cardiac side effects of psychiatric drugs.A suspected case of carbimazole-associated torsades de pointes QT Prolongation Complicated with Torsades de Pointes in Prosthetic Mitral Valve Endocarditis: A Case Report Overdrive pacing in a patient with incessant torsades de pointes.Importance of QT interval in clinical practice.A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.State-dependent blockade of human ether-a-go-go-related gene (hERG) K(+) channels by changrolin in stably transfected HEK293 cells.The association of serum testosterone levels and ventricular repolarization Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.Antibiotic precautions in athletes Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria.Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?Domperidone-induced dystonia: a rare and troublesome complication hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse.Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes.

P2860

Q24634668-B8932A7D-9BB2-4760-86B5-8AD4D46E27BB Q24646866-062504C2-1B19-474E-9562-EA682881D857 Q24683903-7AA3E548-E78F-4089-A825-A6C72F6B6CB0 Q26801610-9A1852F7-5443-4705-A8E4-58AEA6F3776B Q27027096-184FFEA3-4730-437B-8F66-637F85B58674 Q27335021-804CEB68-DBBB-4DB4-A59E-EACE4F3872D5 Q27343160-F4D582D5-4C00-49B7-A622-59E5EDB4E8A8 Q28071256-3EC3C28B-5F2E-460E-8C13-AA33A9A0FEE7 Q28078430-B88CBEEB-D08A-4BF8-93CE-FDCACC4D36FB Q28268128-DA110647-C55B-48EC-BE3F-84AD8E431C3B Q28472692-34719B84-0C59-4BEA-8764-AF2F49E63502 Q28485993-37B425C5-D88E-4879-89C9-52936B85C350 Q28539543-F71C1649-151D-4A86-B018-40FDC17B504C Q28661910-58B6B490-2DBD-45E7-9136-CEA42BFD7C33 Q30474909-75ED8C2C-8692-4117-8948-C289F8B8920C Q30620268-5A1C97F9-060A-422A-AB1A-1307ABCFD20D Q30858387-F6A72329-3F99-4DDD-86B3-92F00E31906E Q31140927-5701CB14-4F3B-479D-AA3C-F6251E1A11B0 Q33155805-897A3C5D-27D1-4AC6-A1C5-8DCB140CE8A0 Q33158936-0865F2AE-2B50-4D36-B291-7A97339962ED Q33161933-E37C5060-6390-4069-9E98-8D2EBE573D3F Q33163390-A4546FD2-8CD0-4BDE-9AF2-074D8D27882C Q33165222-9D2B9C8E-5C0C-484E-B9E9-9FF0823CBE2F Q33479407-2F09ACFC-50A0-4EF7-88BE-99CD0196B331 Q33557841-C5A67FCF-5EF3-4AF3-B5A0-91F63F35762F Q33596419-229F325B-1B1E-478D-8004-C99D87E2BA90 Q33635283-0DE815C0-4589-4104-B843-F720A825B3D7 Q33661017-84A1850A-C760-48FB-9933-A1B66A55E54A Q33765011-1E493212-E55F-4087-BAA2-CDBD2123D3E0 Q33786181-D45D9098-48C7-41A4-BDCF-35D4EB79BD42 Q33794334-EB3955CD-11EE-4FA6-ABF2-0C027B45AD7A Q33810580-9985A3DB-FABA-417E-8452-40B5384C081F Q33810586-66F573AC-4C19-4882-AE2C-2B34F2E1080D Q33833735-9708ACDC-312E-40D2-B032-0A3D3981529C Q33845924-2564DE9B-FE6A-4D29-95AC-9CA10119E3BD Q33883248-904FD250-C7E7-4E1D-B0E3-B2E8D8175577 Q33983552-EA6B8A6A-466F-4E8E-9CD7-80CA105AF094 Q34016220-C488CF6C-E5A3-4171-9655-943C7BD7E2E8 Q34041767-507CCDA1-9CF6-49B7-8353-6E95CBC6C5EF Q34078226-87E1EBF8-1EB7-4B29-83A0-5DC98B315664

P2860

Drug induced QT prolongation and torsades de pointes

http://www.wikidata.org/entity/Q24673854

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Drug induced QT prolongation and torsades de pointes

@ast

Drug induced QT prolongation and torsades de pointes

@en

Drug induced QT prolongation and torsades de pointes

@nl

type

label

Drug induced QT prolongation and torsades de pointes

@ast

Drug induced QT prolongation and torsades de pointes

@en

Drug induced QT prolongation and torsades de pointes

@nl

prefLabel

Drug induced QT prolongation and torsades de pointes

@ast

Drug induced QT prolongation and torsades de pointes

@en

Drug induced QT prolongation and torsades de pointes

@nl

P1433

Q24673854-47C7F5A8-DF33-4404-85FD-B8AF8B1D40EE

P1476

Q24673854-66365EF8-E1EB-4087-960A-EDDB5648A87D

P2093

Q24673854-06CFCA32-0918-4525-A685-0D125A104052

Q24673854-B54D6599-19A5-401E-8C41-ECE95F8CC054

P2860

Q24673854-12278A9E-0A83-4998-9662-8416CBCC4788

Q24673854-22ED2995-EA8F-41B8-BC7D-0C64F65E110C

Q24673854-3F6F2F1F-4023-42A9-99AC-65CE5C3ADB30

Q24673854-4208A783-9D12-4FBC-AE05-1AFBEF01B1FC

Q24673854-75675D20-B05A-4047-9807-3CFAB26B77E9

Q24673854-86C3A741-33F8-4927-89DA-BD1B7E1A1B5C

Q24673854-8741DBC4-54A0-4207-ABB9-CDC5671005C7

Q24673854-97723E5D-A183-463D-A9B3-95A449F4CD20

Q24673854-E5BBCAF9-9036-4636-B9A3-61F0DB03C08A

P304

Q24673854-DD2015FE-E5E3-43FD-8EF0-7B6940C5EC72

P31

Q24673854-BFA9133C-CFF4-43F4-B232-A9E1055312D3

P3181

Q24673854-E3850C03-D565-49E1-AC28-56733A0E6C87

P356

Q24673854-6E3EF54A-3065-4138-8B3A-772CE719D879

P407

Q24673854-617C51CB-9586-409D-AEA8-19C702BA0816

P433

Q24673854-C2428823-EEF4-4B91-9EF7-CDA93969A95E

P478

Q24673854-AEC107CE-9CFC-4CFD-B1D2-962D87928DFD

P577

Q24673854-D7F17581-A3B5-4322-A5C4-70BCC721B95E

P5875

Q24673854-1E2B8D77-1974-4418-A031-39CFA719584E

P698

Q24673854-8ABB2B48-029B-4601-9C81-E866DFA58C9E

P932

Q24673854-F1D996F7-44FE-4C21-87DA-14FFE07565DE

P3181

P356

HEART.89.11.1363

P1433

P1476

Drug induced QT prolongation and torsades de pointes

@en

P2093

A John Camm

http://www.w3.org/2001/XMLSchema#string

Yee Guan Yap

http://www.w3.org/2001/XMLSchema#string

P2860

The long-QT syndrome Genetic considerations.

Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes.

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.

The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.

How to measure the QT interval--what is normal?

Torsades de pointes induced by erythromycin.

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.

A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.

P304

1363-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1994437

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/HEART.89.11.1363

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277511106

http://www.w3.org/2001/XMLSchema#string

P698

14594906

http://www.w3.org/2001/XMLSchema#string

P932

1767957

http://www.w3.org/2001/XMLSchema#string